IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all
Consumer electronics juggernaut Apple (AAPL) is fanning out into new markets, including its recently unveiled smart watch and a rumored car project, leaving its top suppliers to contemplate their next moves as well. Apple has been a mainstay on the IBD 50 list of top-rated stocks along with three of its key suppliers: radio-frequency chipmaker Avago Technologies (AVGO), smartphone and power management chipmaker Skyworks Solutions (SWKS), and
Investors who track where mutual funds and other big investing firms are putting their money have insight into which stocks will be moving up. Today’s Screen Of The Day is Accelerating Mutual Fund Ownership, spotlighting stocks that mutual funds have been scooping up for the past three quarters. Today’s screen focuses on Mellanox Technologies (MLNX) and Inphi (IPHI), a pair of chip stocks that mutual funds are buying as M&A activity heats up in